EGFR and HER2 expression in advanced biliary tract cancer

Table 1 Characteristics of patients with advanced biliary tract cancer

Patients (n = 124)	n (%)
Age (yr)
Range	32.8-84.8
Median	64.8
mean ± SD	63.4 ± 11.0
Male:female	61:63 (49:51)
Gallbladder cancer	33 (26.6)
Mass forming type	47 (37.9)
Intraductal growth type	44 (35.5)
Histological type
Well differentiated	8 (6.5)
Moderately differentiated	80 (64.5)
Poorly differentiated	36 (29)
Stage1
I	9 (7.3)
II	20 (16.1)
III	31 (25)
IV	64 (51.6)
Chemotherapy	62 (50)
Partial response	9 (14.5)
Stable disease	27 (43.5)
Progressive disease	26 (42)

¹According to AJCC/UICC classification 2002.

Table 2 EGFR and HER2 expression and clinicopathological factors (Cox’s model)

Parameter	EGFR 2+ and 3+ tumors	P	HER2 2+ and 3+ tumors	P
Gallbladder cancer	5/13		8/34
Mass forming type	6/24	0.088	7/47	0.517
Intraductal growth type	11/19		10/43
Histological type
Well differentiated	2/3		1/8
Moderately differentiated	16/39	0.511	20/80	0.202
Poorly differentiated	4/14		4/36
Stage1
I	3/4		4/9
II	2/6	0.317	4/20	0.059
III	8/17		9/31
IV	9/29		8/64
Chemotherapy
Partial response	2/3		4/9
Stable disease	3/13	0.296	4/27	0.156
Progressive disease	5/13		5/26

¹According to AJCC/UICC classification 2002.